Hemfer FCM 1k Injection contains Ferric Carboxymaltose (50 mg/ml), an intravenous iron preparation indicated for the treatment of iron deficiency anemia when oral iron preparations are ineffective or cannot be used. Ferric Carboxymaltose provides a stable complex that allows controlled release of bioavailable iron, facilitating rapid replenishment of iron stores and correction of anemia. This formulation is particularly useful in patients with chronic kidney disease, inflammatory bowel disease, heavy uterine bleeding, or those undergoing chemotherapy, where iron deficiency is common and oral supplementation is insufficient. Hemfer FCM 1k Injection is administered intravenously, allowing for high-dose iron delivery in a single or divided doses, minimizing the need for multiple administrations and improving patient compliance. The pharmacokinetic profile supports efficient uptake by the reticuloendothelial system and incorporation into hemoglobin synthesis. Common adverse effects may include transient headache, nausea, dizziness, and injection site reactions, while serious hypersensitivity reactions are rare but require immediate medical attention. Hemfer FCM 1k Injection should be used under medical supervision with appropriate monitoring of iron parameters, hemoglobin levels, and patient response to therapy. It is contraindicated in patients with known hypersensitivity to ferric carboxymaltose or any excipients, and caution is advised in those with iron overload disorders.